Clinical Trial

EPX-HTG for Structural Heart Procedures

Study acronym: EPX-HTG-2026
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
To investigate and evaluate the benefits of adding EchoPixel Holographic Therapy Guidance to the current standard of care in Structural Heart (SH) procedures. Current structural heart (SH) procedures rely on standard image guidance (SIG) relies on 2D X-plane or multiplanar reformatted (MPR) views that can conceal critical anatomy elements at the time of implant or therapy delivery which are crucial to achieve an optimal long term durable outcome. This limitation complicates an operator's task of optimally implanting a 3D device, delivered by tools that rotate and maneuver in 3D, within a dynamic 3D anatomy, the heart. Slight mismatches between the device and the target in the heart are indicative of a sub-optimal device position, a key risk-factor of peri-device leak (PDL) and other complications. The primary objective of the study is to determine if including EchoPixel - HTG as an additive visualization procedural tool has a positive impact on optimal procedure outcomes for patients undergoing in Structural Heart (SH) procedures.
Trial Details
NCT Number NCT07705425
Lead Sponsor EchoPixel, Inc.
Conditions Atrial Fibrillation (AF), Mitral Valve (MV) Regurgitation
Enrollment 20 participants
Start Date 2026-08-03
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15